amiselimod

Evidence outlook · lead readout

NCT04857112 · Ulcerative Colitis

The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.

NCT04857112: The trial randomized 322 participants to low-dose amiselimod, high-dose amiselimod, or placebo under double-blind conditions, with change in the modified Mayo Score—including endoscopic and clinical disease measures—as the primary endpoint. Because the registry has not posted the primary comparison results, whether the endpoint was met is unknown.